SGCB and chronic obstructive pulmonary disease: To the best of our knowledge, this systematic review is the first to summarize existing evidence regarding the effects of pharmacotherapeutic agents targeting the NO-sGC-cGMP pathway on clinical outcomes in PH patients due to COPD.